<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00756873</url>
  </required_header>
  <id_info>
    <org_study_id>Etoric-TE-1</org_study_id>
    <nct_id>NCT00756873</nct_id>
  </id_info>
  <brief_title>Etoricoxib in Ear Nose Throat Surgery</brief_title>
  <official_title>Analgesic Efficacy and Safety of Etoricoxib in Ear Nose Throat Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Regensburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Regensburg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to test the analgesic efficacy of etoricoxib (90 mg or 120 mg qd.
      perioperatively) for post-operative pain relief.

      The primary endpoint is as follows:

        -  does preoperative etoricoxib reduce the post-operative opioid utilization in patients
           undergoing elective tonsillectomy under general anaesthesia (i.e. the post-operative
           opioid-sparing effect of etoricoxib in humans).

      The secondary endpoints are as follows:

        -  does the etoricoxib medication have an impact on PONV or activities of daily

        -  does the etoricoxib medication influence the blood loss during surgery or the incidence
           of postoperative bleeding

        -  does the etoricoxib medication influence the operation time. In addition, adverse
           effects of etoricoxib will be documented.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      On day of surgery (day 0) the patients will be randomly assigned to one of the three groups
      using a sealed envelope method. The etoricoxib 90 mg group receives etoricoxib (Arcoxia®,
      Merck Sharp &amp; Dohme GmbH, Haar, Germany) 90 mg orally, the etoricoxib 120 mg group receives
      etoricoxib 120 mg orally and the control group receives a placebo tablet orally 1 h before
      surgery (day 0). All patients receive a standard general anesthesia with intravenous propofol
      (2-3 mg/kg), fentanyl (2 µg/kg) and mivacurium (0.2 mg/kg) for induction. Patients are
      ventilated via a tracheal tube, anesthesia being maintained with sevoflurane (0.8 - 1.5%
      end-tidal concentration). If mean arterial blood pressure or heart rate increase to more than
      25% above the pre-operative baseline value despite an end-tidal concentration of 1.5%
      sevoflurane, an intravenous bolus of fentanyl 0.05 mg will be administered. Monitoring
      includes electrocardiogram (ECG), non-invasive arterial blood pressure, pulse oximetry,
      end-tidal CO2 and end-tidal sevoflurane. On days 1 to 3 patients will receive etoricoxib (90
      mg or 120 mg qd.) or placebo. After discharge on day 3, patients will receive etoricoxib (90
      mg or 120 mg qd.) or placebo until cessation of pain during activity (swallowing). According
      to the current label for Arcoxia® 120 mg in Germany, patients taking etoricoxib 120 mg will
      switch to etoricoxib 90 mg on day 8. Rescue medication will be piritramid i.v. (day 0),
      oxycodone p.o. (day 1-2) and paracetamol p.o. (day 3-14).

      Day -7 to -1: Inclusion/exclusion criteria, medical history, concomitant medications,
      laboratory, serum pregnancy test, informed consent Day 0: Study medication 1 h before
      surgery, intra-operative blood loss, pain score, opioid utilization, PONV score and
      anti-emetic medication Day 1: pain score, opioid utilization, PONV score, anti-emetic
      medication, bleeding Day 2: pain score, opioid utilization, PONV score, anti-emetic
      medication, bleeding Day 3: pain score, opioid utilization, PONV score, anti-emetic
      medication, bleeding Day 7: pain score, paracetamol utilization, bleeding Day 14: first day
      with no pain, last study medication, paracetamol utilization, bleeding
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>October 2008</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <primary_completion_date type="Anticipated">September 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-operative opioid-sparing effect of etoricoxib in humans undergoing elective tonsillectomy</measure>
    <time_frame>Day 0-3 after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact of etoricoxib medication on PONV or activities of daily or the incidence of postoperative bleeding</measure>
    <time_frame>Day 0-14</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Tonsillectomy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Etoricoxib 90 mg qd.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Etoricoxib 120 mg qd. (day 0-7) Etoricoxib 90 mg qd. (day 8-14)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Administration of placebo</intervention_name>
    <description>Placebo qd orally day 0-14</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Administration of etoricoxib</intervention_name>
    <description>Etoricoxib 90 mg qd orally day 0-14</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Administration of etoricoxib</intervention_name>
    <description>Etoricoxib 120 mg qd orally day 0-7 Etoricoxib 90 mg qd orally day 8-14</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male or female patients

          -  18 years of age

          -  female patients not pregnant/non-lactating

          -  indication for elective tonsillectomy

          -  written informed consent.

        Exclusion Criteria:

          -  etoricoxib, other analgesic or anti-emetic medication within 10 half-lives

          -  evidence for active peptic ulceration

          -  history of gastrointestinal bleeding

          -  evidence of hepatic, renal or hematopoietic disorders

          -  heart failure (NYHA II-IV)

          -  uncontrolled arterial hypertension

          -  clinical evidence of arterial occlusive disease

          -  coronary heart disease or cerebrovascular disease

          -  inflammatory bowel disease

          -  hypersensitivity to analgetics, antipyretics, NSAIDs or antiemetics

          -  evidence for noncompliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Michael Bucher, MD, PhD</last_name>
    <phone>xx49-941-944-</phone>
    <phone_ext>0</phone_ext>
    <email>michael.bucher@klinik.uni-regensburg.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universtiy Hospital Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Bucher, MD, PhD</last_name>
      <phone>xx49-941-944-</phone>
      <phone_ext>0</phone_ext>
      <email>michael.bucher@klinik.uni.regensburg.de</email>
    </contact>
    <investigator>
      <last_name>Michael Bucher, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Kühnel, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weiden Clinic</name>
      <address>
        <city>Weiden i.d. OPf.</city>
        <zip>92637</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jürgen Altmeppen, MD</last_name>
      <phone>xx49-9 61-303-</phone>
      <phone_ext>32 02</phone_ext>
      <email>anaesthesie@klinikum-weiden.de</email>
    </contact>
    <investigator>
      <last_name>Jürgen Altmeppen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2008</study_first_submitted>
  <study_first_submitted_qc>September 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2008</study_first_posted>
  <last_update_submitted>September 19, 2008</last_update_submitted>
  <last_update_submitted_qc>September 19, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2008</last_update_posted>
  <responsible_party>
    <name_title>Michael Bucher, MD, PhD</name_title>
    <organization>University Hospital Regensburg</organization>
  </responsible_party>
  <keyword>Elective tonsillectomy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoricoxib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

